135 related articles for article (PubMed ID: 17657838)
1. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.
Hagiwara T; Kato M; Anbo T; Imamura A; Suga T; Uchida T; Fujinaga A; Nakagawa M; Nakagawa S; Shimizu Y; Yamamoto J; Takeda H; Asaka M
World J Gastroenterol; 2007 Jul; 13(28):3836-40. PubMed ID: 17657838
[TBL] [Abstract][Full Text] [Related]
2. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
Kim N; Park SH; Seo GS; Lee SW; Kim JW; Lee KJ; Shin WC; Kim TN; Park MI; Park JJ; Hong SJ; Shim KN; Kim SW; Shin YW; Chang YW; Chun HJ; Lee OJ; Jeon WJ; Park CG; Cho CM; Park CH; Won SY; Lee GH; Park KS; Shin JE; Kim HU; Park JY; Chae HS; Song GA; Kim JG; Yoon BC; Seol S; Jung HC; Chung IS
Helicobacter; 2008 Dec; 13(6):542-9. PubMed ID: 19166420
[TBL] [Abstract][Full Text] [Related]
3. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Isomoto H; Inoue K; Furusu H; Nishiyama H; Shikuwa S; Omagari K; Mizuta Y; Murase K; Murata I; Kohno S
Helicobacter; 2003 Apr; 8(2):111-9. PubMed ID: 12662378
[TBL] [Abstract][Full Text] [Related]
4. Lafutidine-based triple therapy for Helicobacter pylori eradication.
Ren Q; Ma B; Yang K; Yan X
Hepatogastroenterology; 2010; 57(102-103):1074-81. PubMed ID: 21410034
[TBL] [Abstract][Full Text] [Related]
5. Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study.
Kudo T; Fujinami H; Ando T; Nishikawa J; Ogawa K; Hosokawa A; Orihara T; Murakami J; Takahara T; Sugiyama T
Helicobacter; 2012 Aug; 17(4):277-81. PubMed ID: 22759327
[TBL] [Abstract][Full Text] [Related]
6. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
[TBL] [Abstract][Full Text] [Related]
7. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
[TBL] [Abstract][Full Text] [Related]
8. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
9. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
Graham DY; Hammoud F; El-Zimaity HM; Kim JG; Osato MS; El-Serag HB
Aliment Pharmacol Ther; 2003 May; 17(10):1229-36. PubMed ID: 12755836
[TBL] [Abstract][Full Text] [Related]
11. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Asaka M; Kato M; Sugiyama T; Satoh K; Kuwayama H; Fukuda Y; Fujioka T; Takemoto T; Kimura K; Shimoyama T; Shimizu K; Kobayashi S;
J Gastroenterol; 2003; 38(4):339-47. PubMed ID: 12743773
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Sancar M; Izzettin FV; Apikoglu-Rabus S; Besisik F; Tozun N; Dulger G
Pharm World Sci; 2006 Aug; 28(4):207-14. PubMed ID: 17066247
[TBL] [Abstract][Full Text] [Related]
13. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
Lamouliatte H; Cayla R; Zerbib F; Forestier S; de Mascarel A; Joubert-Collin M; Mégraud F
Am J Gastroenterol; 1998 Sep; 93(9):1531-4. PubMed ID: 9732938
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two different treatment protocols in Helicobacter pylori eradication.
Nadir I; Yonem O; Ozin Y; Kilic ZM; Sezgin O
South Med J; 2011 Feb; 104(2):102-5. PubMed ID: 21206418
[TBL] [Abstract][Full Text] [Related]
16. Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
Grgov S; Tasić T; Radovanović-Dinić B; Benedeto-Stojanov D
Vojnosanit Pregl; 2016 Nov; 73(11):1044-9. PubMed ID: 29328644
[TBL] [Abstract][Full Text] [Related]
17. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy.
Kim SY; Lee SW; Hyun JJ; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Choi JH
J Clin Gastroenterol; 2013 Jan; 47(1):21-4. PubMed ID: 22647826
[TBL] [Abstract][Full Text] [Related]
19. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
Cindoruk M; Erkan G; Karakan T; Dursun A; Unal S
Helicobacter; 2007 Aug; 12(4):309-16. PubMed ID: 17669103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
